Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2426 | Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances Wiki | 0.71 |
drug2490 | Placebo Wiki | 0.05 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to assess the safety, tolerability, and immunization of Nanocovax in healthy volunteers.
Description: Percentage and severity level of participants reporting Solicited adverse events
Measure: Solicited adverse events Time: 7 days after each doseDescription: Geometric mean concentrations of Anti-S IgG at each time points
Measure: Anti-S IgG Time: 0, 7, 28, 35, 56, 180 days after the first doseDescription: Geometric mean titers of SARS-CoV-2 Neutralization antibody at each time points
Measure: SARS-CoV-2 neutralizing titers Time: 0, 7, 28, 35, 56, 180 days after the first doseDescription: Proportion of participants achieving ≥4-fold rise of Anti-S IgG from before vaccination at each time points
Measure: Participants achieving ≥4-fold rise of Anti-S IgG Time: 0, 7, 28, 35, 56, 180 days after the first doseDescription: Change of IFNγ from baseline after vaccination
Measure: Cellular immune response (IFNγ) Time: 28, 35, 56 days after the first doseDescription: Change of T CD4 from baseline after vaccination
Measure: Cellular immune response (T CD4) Time: 28, 35, 56 days after the first doseDescription: Change of T CD8 from baseline after vaccination
Measure: Cellular immune response (T CD8) Time: 28, 35, 56 days after the first doseDescription: Percentage of participants reporting Serious adverse events
Measure: Serious adverse events Time: 28 days after each doseDescription: Percentage of participants reporting Unsolicited adverse events
Measure: Unsolicited adverse events Time: 28 days after each doseAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports